Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human

High Efficacy of a Listeria-Based Vaccine against Metastatic Breast Cancer Reveals a Dual Mode of Action

(2009) S. H. Kim et al.   CANCER RESEARCH

A Novel Human Her-2/neu Chimeric Molecule Expressed by Listeria monocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors

(2009) M. M. Seavey et al.   CLINICAL CANCER RESEARCH

The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix

(2009) Paulo Cesar Maciag et al.   VACCINE

Development of a Listeria monocytogenes based vaccine against prostate cancer

(2008) Vafa Shahabi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Construction and Characterization of an Attenuated Listeria monocytogenes Strain for Clinical Use in Cancer Immunotherapy

(2008) A. Wallecha et al.   Clinical and Vaccine Immunology

Can We Circumvent Resistance To ErbB2-Targeted Agents By Targeting Novel Pathways?

(2008) Mark Pegram   Clinical Breast Cancer

Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells

(2008) S. Ladoire et al.   CLINICAL CANCER RESEARCH